MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Chen, Dengyu ^a,b   Zhang, Yunxia ^a   Wang, Jing ^a   Chen, Junsong ^a   Yang, Cuiping ^a   Cai, Kai ^a   Wang, Xiaoying ^a   Shi, Fangfang ^a   Dou, Jun ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b BENGBU COLLEGE   (China)

Author keywords

Cancer stem cells; Epithelial ovarian cancer; Epithelial mesenchymal transition; Metastasis; MiRNAs 200c

Indexed keywords

HERMES ANTIGEN; MICRORNA 200C; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER STEM CELL; CARCINOGENICITY; CELL MIGRATION; CELL MOTILITY; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LENTIVIRINAE; LUNG METASTASIS; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WOUND CLOSURE; WOUND HEALING;

EID: 84879996033     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-50     Document Type: Article

References (37)

1. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Bendoraite A, Knouf EC, Garg KS, Gynecol Oncol 2010 116 117 125 10.1016/j.ygyno.2009.08.009 19854497
2. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M, Lancet Oncol 2011 12 273 285 10.1016/S1470-2045(11)70012-2 21345725
3. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC, J Ovarian Res 2012 5 44 10.1186/1757-2215-5-44 23237306
4. Mechanisms promoting physiological cells progression into tumorigenesis. Korbut E, Ptak-Belowska A, Brzozowski T, J Physiol Pharmacol 2012 63 565 570 23388471
5. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein- related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA, PLoS One 2013 8 57056 10.1371/journal.pone.0057056 23451143
6. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T, Mor G, Oncogene 2013 32 39 49 10.1038/onc.2012.33 22349827
7. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK, Mol Cancer Ther 2012 11 2556 2565 10.1158/1535-7163.MCT-12-0463 23074172
8. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial- mesenchymal transition. Bracken CP, Gregory PA, Kolesnikoff N, Cancer Res 2008 68 7846 7854 10.1158/0008-5472.CAN-08-1942 18829540
9. Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse. He X, Wang J, Zhao F, Yu F, Chen D, Cai K, Yang C, Chen J, Dou J, Immunol Res 2012 52 240 249 10.1007/s12026-012-8332-4 22477528
10. MicroRNA expression profiles in serous ovarian carcinoma. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S, Clin Cancer Res 2008 14 2690 2695 10.1158/1078-0432.CCR-07-1731 18451233
11. The epithelial- mesenchymal transition generates cells with properties of stem cells. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA, Cell 2008 133 704 715 10.1016/j.cell.2008.03.027 18485877 (Pubitemid 351636299)
12. Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. Berry NB, Bapat SA, J Ovarian Res 2008 1 8 10.1186/1757-2215-1-8 19025622
13. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK, Oncogene 2009 28 209 218 10.1038/onc.2008.374 18836486
14. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. Ho CM, Chang SF, Hsiao CC, Chien TY, Shih DT, J Biomed Sci 2012 19 23 10.1186/1423-0127-19-23 22330345
15. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP, Cancer Res 2008 68 4311 4320 10.1158/0008-5472.CAN-08-0364 18519691
16. +ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, Zhang H, Dou J, BMC Cell Biol 2013 14 7 10.1186/1471-2121-14-7 23368632
17. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L, Zhao F, Jiang C, Hu W, Hu K, Gu N, Cell Mol Immunol 2007 4 467 472 18163959
18. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Choi YP, Shim HS, Gao MQ, Kang S, Cho NH, Cancer Lett 2011 307 62 71 10.1016/j.canlet.2011.03.018 21481528
19. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M, Cancer Res 2011 71 6320 6326 10.1158/0008-5472.CAN-11-1021 21862635
20. miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1. Liu SJ, Tetzlaff MT, Cui R, Xu X, Am J Pathol 2012 181 1823 1835 10.1016/j.ajpath.2012.07.009 22982443
21. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T, EMBO Rep 2008 9 582 589 10.1038/embor.2008.74 18483486 (Pubitemid 351772923)
22. Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D, Gu N, Cell Biol Int 2011 35 227 234 10.1042/CBI20100347 21108606
23. Identification of tumor stem-like cells in a mouse myeloma cell line. Dou J, Li Y, Zhao F, Hu W, Wen P, Tang Q, Chu L, Wang Y, Cao M, Jiang C, Gu N, Cell Mol Biol (Noisy-le-Grand) 2009 55 Suppl L1151 OL1160
24. Characterization of clonogenic multiple myeloma cells. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ, Blood 2004 103 2332 2336 10.1182/blood-2003-09-3064 14630803 (Pubitemid 38326254)
25. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J, Br J Cancer 2012 106 1486 1494 10.1038/bjc.2012.130 22472882
26. Membrane-bound and exosomal metastasis- associated C4.4A promotes migration by associating with the α(6)β(4) integrin and MT1-MMP. Ngora H, Galli UM, Miyazaki K, Zöller M, Neoplasia 2012 14 95 107 22431918
27. Cellular response to gene expression profiles of different hepatitis C virus core protein in Huh-7 cell line with microarray analysis. Dou J, Liu P, Zhang X, J Nanosci Nanotechnol 2005 5 1230 1235 10.1166/jnn.2005.209 16193983 (Pubitemid 44502135)
28. Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Hu W, Wang J, Dou J, He X, Zhao F, Jiang C, Yu F, Hu K, Chu L, Li X, Gu N, Cell Transplant 2011 20 669 680 10.3727/096368910X536509 21054951
29. Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Yu F, Wang J, Dou J, Yang H, He X, Xu W, Zhang Y, Hu K, Gu N, Nanomedicine 2012 8 1337 1344 10.1016/j.nano.2012.02.015 22406425
30. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis. Hu K, He X, Yu F, Yuan X, Hu W, Liu C, Zhao F, Dou J, Immunol Invest 2011 40 265 278 10.3109/08820139.2010. 534219 21204603
31. MicroRNA signatures in human ovarian cancer. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM, Cancer Res 2007 67 8699 8707 10.1158/0008-5472.CAN-07-1936 17875710 (Pubitemid 47437445)
32. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang Y, Wood W III, Becker KG, Morin PJ, PLoS One 2008 3 2436 10.1371/journal.pone. 0002436 18560586
33. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF, Gynecol Oncol 2011 121 200 205 10.1016/j.ygyno.2010.12.339 21277012
34. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G, Proc Natl Acad Sci USA 2008 105 7004 7009 10.1073/pnas.0801615105 18458333 (Pubitemid 351754520)
35. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, Shih IM, Am J Surg Pathol 2010 34 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
36. Ovarian cancer development and metastasis. Lengyel E, Am J Pathol 2010 177 1053 1064 10.2353/ajpath.2010.100105 20651229
37. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, Zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T, Nat Cell Biol 2009 12 1487 1495